AI Scans 400,000 Reddit Posts to Reveal Hidden GLP-1 Side Effects
Researchers at the University of Pennsylvania used artificial intelligence to analyze hundreds of thousands of Reddit posts and uncovered symptoms linked to popular weight-loss drugs like Ozempic and Mounjaro that are rarely captured in clinical trials or drug labeling. The findings, published in Nature Health in April 2026, suggest that social media can serve as an early-warning system for adverse drug reactions.
Popular glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide have transformed treatment for type 2 diabetes and obesity. But their safety profile is more complex than clinical trials suggest, according to a large-scale analysis of patient-reported symptoms from Reddit that reveals a spectrum of side effects often absent from regulatory documents.
The study, led by doctoral student Neil K. R. Sehgal at the University of Pennsylvania School of Engineering and Applied Science, analyzed 410,198 Reddit posts across nine weight-management subreddits posted between May 2019 and June 2025. Of the 67,008 unique users who self-reported using GLP-1 medications, 43.5 percent described at least one side effect. The most commonly reported symptoms included gastrointestinal distress, fatigue, and reproductive changes.
Key Finding: Nearly 4 percent of Reddit users with side effects reported reproductive symptoms, including menstrual irregularities, intermenstrual bleeding, and heavy bleeding. Researchers called this a signal worth investigating, especially given that Reddit skews male and the true rate among women could be higher. Source: Nature Health, 2026.
The Gap Between Trials and Real-World Experience
Clinical trials remain the gold standard for identifying dangerous adverse drug events. But they are designed, by necessity, around controlled populations and predefined endpoints. Patients who stop taking a medication because of side effects, those with comorbidities excluded from trials, and people using drugs off-label all escape clinical trial sampling entirely.
“The whole point of this kind of approach is that it can move quickly, and that’s exactly when it is most valuable,” Sharath Chandra Guntuku, a senior author and Research Associate Professor of Computer and Information Science at Penn Engineering, told reporters. “Clinical trials are the gold standard, but by design, they are slow.”
The researchers used large language models to map the free-form language of Reddit posts onto the standardized Medical Dictionary for Regulatory Activities (MedDRA) that clinicians use to classify symptoms. This process allowed them to identify symptom clusters that had not met traditional pharmacovigilance thresholds. One of the most notable findings was fatigue, which emerged as the second most commonly reported adverse symptom in the Reddit data despite registering relatively low rates in clinical trial reports.
Methodology: The team analyzed posts from nine large subreddits discussing GLP-1 medications. A sub-analysis of 29,172 users who disclosed at least one side effect found that 61.5 percent exclusively mentioned semaglutide formulations and 24.4 percent exclusively mentioned tirzepatide formulations. Source: arXiv preprint 2603.12341.
What the Data Revealed
The automated analysis produced a detailed taxonomy of reported side effects. Beyond well-known gastrointestinal symptoms, the study highlighted several categories of underreported adverse events:
Reproductive and menstrual symptoms: Approximately 4 percent of users with side effects reported reproductive complaints, including intermenstrual bleeding (0.9 percent), heavy bleeding (0.9 percent), and irregular cycles (0.7 percent). Menstrual irregularities were among the most frequently cited symptoms that do not appear prominently in current prescribing information.
Temperature-related complaints: Chills and hot flashes were commonly discussed across multiple subreddits. These systemic symptoms, while generally benign, affect quality of life and were not captured with sufficient frequency in structured trial data to reach reporting thresholds.
Psychiatric symptoms: The analysis also surfaced reports of mood changes, including depressive symptoms and anxiety, that have received limited attention in the GLP-1 pharmacovigilance literature despite growing patient concern.
Persistent nausea and vomiting: While these effects are known to GLP-1 users and present in trial data, the Reddit analysis revealed that their persistence in the real world appears more severe than clinical trial averages suggest, particularly among women who experience these symptoms at 2.5 times the rate of male patients.
Kidney function: Prior analyses of the FDA’s Adverse Event Reporting System (FAERS) database have identified a disproportionality signal for acute kidney injury associated with semaglutide. Although the Reddit analysis did not directly address renal outcomes, several users discussed symptoms consistent with renal strain, particularly in the context of rapid weight loss and dehydration.
| Symptom Category | Reddit Report Rate | Clinical Trial Coverage | Key Concern |
|---|---|---|---|
| Gastrointestinal (nausea, vomiting) | High | Well documented | Persistent in real-world use, higher in women |
| Fatigue | 2nd most reported | Low reporting thresholds | Significant quality-of-life impact |
| Reproductive/menstrual | ~4 percent | Underrepresented | Sparse in prescribing info |
| Temperature-related | Commonly cited | Minimal | Chills and hot flashes affect daily function |
| Psychiatric | Emerging signal | Limited | Growing patient concern |
Why the Method Matters
The study represents one of the largest attempts to apply machine-learning tools to pharmacovigilance. Large language models have advanced sufficiently to process the vast variability in how patients describe symptoms, overcoming a longstanding barrier in social media-based adverse event detection.
“Some of the side effects we found, like nausea, are well known, and that shows that the method is picking up a real signal,” Guntuku said. “The underreported symptoms are leads that came from patients themselves, unprompted, and clinicians could potentially pay attention to them.”
Lyle Ungar, a co-author and Professor in CIS and Computer Science, emphasized the limitations of the approach. Social media is not representative of the broader patient population, and correlation does not imply causation. The Reddit user base skews male, is younger than typical clinical populations, and users have self-selected into health communities. None of these factors allows for causal conclusions about whether GLP-1 RAs actually cause the symptoms reported.
“Clinical trials generally identify the most dangerous side effects of drugs,” Ungar noted. “But they can fail to find what symptoms patients are most concerned about, even though a large collection of posts may reflect additional concerns.”
Clinical Implications
The researchers emphasized that their findings should not alter current prescribing practices. GLP-1 receptor agonists remain safe and effective medications for their approved indications, and the well-established benefits outweigh the risks for most patients.
“No changes to clinical practice are warranted now,” the study authors write. “But these signals are worth investigating. When a medication goes from niche to mainstream almost overnight, as GLP-1 RAs have, surveillance that moves quickly matters.”
Independent pharmacovigilance analyses using the FDA’s FAERS database have corroborated concerns about semaglutide and acute kidney injury risk, though those findings also rely on spontaneous reporting and carry their own biases. A separate 2025 study published in Frontiers in Pharmacology analyzed FAERS and social media data together and found that women experience nausea and vomiting at 2.5 times the rate of men on GLP-1 medications.
The authors of the Reddit study suggest that their social media pharmacovigilance approach, which complements rather than replaces the FDA system, could prove most valuable for detecting rare or delayed adverse effects as novel medications reach millions of users in compressed timeframes.
References
- Sehgal, N. K. R., Tronieri, J. S., Ungar, L. & Guntuku, S. C. Self-reported side effects of semaglutide and tirzepatide in online communities. Nature Health (2026). https://www.nature.com/articles/s44360-026-00108-y
- University of Pennsylvania School of Engineering and Applied Science. Penn researchers use AI to surface unreported GLP-1 side effects in Reddit posts. (2026). Available at: https://www.seas.upenn.edu/stories/penn-researchers-use-ai-to-surface-unreported-glp-1-side-effects-in-reddit-posts/
- Medscape. Reddit analysis uncovers unreported GLP-1 side effects. (2026). Available at: https://www.medscape.com/viewarticle/reddit-analysis-uncovers-unreported-glp-1-side-effects-2026a1000bva
- Zhou, Y. et al. Frontiers in Pharmacology. Comparative analysis of semaglutide-induced adverse events from FDA’s FAERS database and social media. Front. Pharmacol. 15, 1471615 (2024). https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1471615/full
- Truveta. Women experience greater side effects but also greater weight loss on GLP-1 medications. (2025). Available at: https://www.truveta.com/blog/research/glp1-side-effects-women-truveta-research/
- Sehgal, N. K. R., Ungar, L. & Guntuku, S. C. Preprint. Self-Reported Side Effects of Semaglutide and Tirzepatide in Online Communities. arXiv 2603.12341 (2026). https://arxiv.org/abs/2603.12341
